Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:11 PM ET 8-K
Leadership Change Biodesix Inc BDSX

Biodesix Leadership Change

Kieran O’Kane, the Chief Commercial Officer of Biodesix, Inc., departed the company effective November 2, 2026. He will be eligible for separation benefits under his existing Executive Severance and Change in Control Agreement as a result of his qualifying termination.

4:11 PM ET 8-K
Financial Results Castle Biosciences Inc CSTL

Castle Biosciences Financial Results

Castle Biosciences reported Q3 2026 revenue of $102.9 million, a 24% increase year-over-year, driven by strong volume growth in its TissueCypher test. The company raised its full-year 2026 revenue guidance to a range of $385-395 million and reported a net loss of $4.1 million for the quarter.

Term
Q3 2026

“Our team delivered another strong quarter, reflecting consistent execution across our portfolio. TissueCypher was a key contributor to our top-line performance, delivering 47% year-over-year growth in test report volume compared to the third quarter of 2025.”

Derek Maetzold, president and chief executive officer of Castle Biosciences
4:11 PM ET 8-K
Financial Results Full House Resorts Inc FLL

Full House Resorts Financial Results

Full House Resorts reported third quarter 2026 consolidated revenues of $81.8 million, a 4.9% increase year-over-year, driven by record performance at American Place Casino. The company reported a net loss of $8.6 million, compared to a $7.7 million loss in the prior-year period, while Adjusted EBITDA remained relatively stable at $14.6 million.

Term
Q3 2026

“Our third quarter results reflect continued momentum across our portfolio, led once again by American Place. Since its opening in February 2023, revenues and profits at American Place have increased in every quarter when compared to the prior-year period.”

Daniel R. Lee, Chief Executive Officer of Full House Resorts

“At Chamonix/Bronco Billy’s, revenues grew across table games, food and beverage, hotel, retail, and several other departments. We are also executing on new initiatives to further advance our profit objectives at the property, while minimizing disruptions to customer service.”

Daniel R. Lee, Chief Executive Officer of Full House Resorts
4:11 PM ET 10-Q
Financial Results Caribou Biosciences, Inc. CRBU

Caribou Biosciences Q3 2026 Results: Net Loss of $26.6M, Loss Narrows

Caribou Biosciences reported a net loss of $76.0 million for the nine months ended September 30, 2026, compared to $121.6 million in the prior year period. Total assets decreased to $123.0 million from $175.4 million at year-end 2025, while the company raised $22.8 million in net proceeds through an at-the-market (ATM) offering during the first nine months of 2026.

Key figure
Net loss $26.6M
4:11 PM ET 8-K
Financial Results Pulse Biosciences, Inc. PLSE

Pulse Biosciences Financial Results

Pulse Biosciences reported third quarter 2026 financial results, highlighted by the completion of enrollment in its NANOPULSE-AF U.S. pivotal IDE study three months ahead of schedule. The company ended the quarter with $189.2 million in cash and equivalents, bolstered by $95.8 million in net proceeds raised through its ATM programs during the period.

“Pulse Biosciences delivered several major milestones since the second quarter, led by completing enrollment in our U.S. pivotal IDE study in just six months, three months ahead of plan. That speed reflects the growing enthusiasm physicians have shown for the nPulse catheter since their very first cases.”

Paul LaViolette, CEO and Co Chairman of Pulse Biosciences

“With NANOPULSE-AF fully enrolled, and the capital to execute, we are now focused on preparations for launch readiness, additional data readouts, and regulatory submissions.”

Paul LaViolette, CEO and Co Chairman of Pulse Biosciences
4:11 PM ET 8-K
Financial Results Caribou Biosciences, Inc. CRBU

Caribou Biosciences Financial Results

Caribou Biosciences reported Q3 2026 financial results, including a GAAP net loss of $26.6 million on revenue of $1.6 million. The company also highlighted its October 2026 decision to discontinue clinical trials for vispa-cel and CB-011 and reduce its workforce while exploring strategic alternatives such as a merger or acquisition.

Term
Q3 2026
4:11 PM ET 8-K
Financial Results EverCommerce Inc. EVCM

EverCommerce Financial Results

EverCommerce reported Q3 2026 revenue of $151.4 million, a 2.7% increase year-over-year, though results fell below the low end of management's guidance due to milestone delays and softness in organic search customer acquisition. The company also announced it repurchased 1.6 million shares for $15.7 million during the quarter and recently increased its total buyback authorization by $25 million.

Term
Q3 2026

“Third quarter revenue was below the low end of our guidance, while Adjusted EBITDA came in at the midpoint. The revenue miss was driven primarily by non-MRR items, including vendor rebates and Security & Alarm milestone delays, along with continued softness in organic search–driven customer acquisition.”

Alex Goor, CEO of EverCommerce

“We’ve made meaningful changes to our leadership team over the last several months, and having spent time across our entire product portfolio, I’m excited by the potential in many areas of our business. We will invest dynamically as we identify opportunities to accelerate growth.”

Alex Goor, CEO of EverCommerce
4:11 PM ET Form 4
Insider Selling Figma, Inc. FIG

Figma CAO Tyler Herb Sells $47.9K of Stock

Tyler Herb, CAO, sold 2,214 shares of Figma, Inc. at $21.26 to $22.00 a share (average $21.63) in 2 transactions, worth $47.9K in total between Nov 3, 2026 and Nov 4, 2026. Shares held after the trade: 241,044 (-0.5%).

Value
$47.9K
Shares
2,214
Average price
$21.63
Role
CAO
Holding change
-0.5%
Trade date
Nov 3, 2026 to Nov 4, 2026
4:11 PM ET 10-Q
Financial Results Tenax Therapeutics, Inc. TENX

Tenax Therapeutics Q3 2026 Results: Net Loss of $16.7M, Loss Widens

Tenax Therapeutics reported a net loss of $50.2 million for the nine months ended September 30, 2026, driven by increased research and development costs for its cardiopulmonary therapies. Despite the loss, the company strengthened its liquidity position to $113.7 million in cash and cash equivalents, primarily through $52.1 million in proceeds from the exercise of warrants and options. Management believes current funds are sufficient to support operations for at least the next 12 months.

Key figure
Net loss $16.7M
4:11 PM ET 8-K
Financial Results CytomX Therapeutics, Inc. CTMX

CytomX Therapeutics Financial Results

CytomX Therapeutics reported Q3 2026 financial results and provided a business update, highlighting that its lead candidate Varsetatug masetecan (Varseta-M) received FDA Fast Track designation for metastatic colorectal cancer. The company expects to provide a Phase 1 monotherapy data update in January 2027 and potentially initiate its first registrational study in the first half of 2027.

“Varseta-M is a first-in-class EpCAM-directed antibody drug conjugate with a topoisomerase-1 inhibitor payload, intentionally designed to improve the standard of care for patients with colorectal and other cancers. At CytomX, we are highly focused on rapidly advancing monotherapy Varseta-M towards a first registrational study in colorectal cancer.”

Dr. Sean McCarthy, chairman and CEO of CytomX Therapeutics

“Additionally, the Varseta-M development program continues to broaden, including an ongoing combination study with bevacizumab in mCRC and the initiation of Phase 1 expansion cohorts in gastric and gastroesophageal junction cancer, EpCAM-selected pancreatic ductal adenocarcinoma, and EpCAM-selected biliary tract cancer. Our integrated strategy is intended to urgently advance Varseta-M for the maximum benefit of cancer patients.”

Dr. Sean McCarthy, chairman and CEO of CytomX Therapeutics
4:11 PM ET 8-K
Financial Results Janux Therapeutics, Inc. JANX

Janux Therapeutics Financial Results

Janux Therapeutics reported financial results for the third quarter ended September 30, 2026, highlighting a strong cash position of $945.7 million. The company continues to advance its clinical pipeline, including dosing the first patient in a Phase 1 study of JANX013 and preparing for an upcoming data presentation for JANX011.

“During the third quarter, we continued to execute across our clinical portfolio, including dosing the first patient in the Phase 1 study of JANX013 in combination with JANX007. We are also preparing to present initial clinical data from JANX011 on November 9. JANX011 was designed to achieve deep B-cell depletion while limiting cytokine release. The upcoming clinical update will provide an initial look at how this differentiated approach translates into humans.”

David Campbell, Ph.D., President and Chief Executive Officer
4:11 PM ET 10-Q
Financial Results Century Aluminum Co CENX

Century Aluminum Q3 2026 Results: Net Income $303M, Up 1930.9% YoY

Century Aluminum reported a significant increase in net income for the nine months ended September 30, 2026, reaching $873.1 million compared to $18.9 million in the prior year, largely driven by a $287.9 million gain on the sale of Hawesville and improved gross profits. Total net sales grew to $2,362.5 million from $1,894.2 million year-over-year, while the company's cash position strengthened to $713.0 million.

Key figure
Net income $303M · +1930.9% YoY
4:11 PM ET Form 4
Insider Selling Alamar Biosciences, Inc. ALMR

Alamar Biosciences 10% Owner Qiming Corporate GP VI Ltd. Sells $3.33M of Stock

Qiming Corporate GP VI Ltd., 10% Owner, sold 111,313 shares of Alamar Biosciences, Inc. at $29.89 a share, worth $3.33M in total on Nov 3, 2026. Shares held after the trade: 1,650,354 (-1.2%).

Value
$3.33M
Shares
111,313
Average price
$29.89
Role
10% Owner
Holding change
-1.2%
Trade date
Nov 3, 2026
4:11 PM ET Form 4
Insider Selling MBX Biosciences, Inc. MBX

MBX Biosciences CMO Salomon Azoulay Sells $20.1K of Stock

Salomon Azoulay, CMO, sold 373 shares of MBX Biosciences, Inc. at $53.96 a share, worth $20.1K in total on Nov 4, 2026. Shares held after the trade: 14,026 (-2.6%).

Value
$20.1K
Shares
373
Price
$53.96
Role
CMO
Holding change
-2.6%
Trade date
Nov 4, 2026
4:11 PM ET Form 4
Insider Selling Neptune Insurance Holdings Inc. NP

Neptune Insurance Holdings CEO Trevor R. Burgess Sells $3.46M of Stock

Trevor R. Burgess, CEO, sold 119,577 shares of Neptune Insurance Holdings Inc. at $28.80 to $29.95 a share (average $28.95) in 3 transactions, worth $3.46M in total between Nov 3, 2026 and Nov 4, 2026. Shares held after the trade: 2,078,236 (-0.2%).

Value
$3.46M
Shares
119,577
Average price
$28.95
Role
CEO
Holding change
-0.2%
Trade date
Nov 3, 2026 to Nov 4, 2026
4:11 PM ET 10-Q
Financial Results CareTrust REIT, Inc. CTRE ▶ Call

CareTrust REIT Q3 2026 Results: Net Income $83.7M, Up 11.7% YoY

CareTrust REIT reported significant growth for the nine months ended September 30, 2026, with total revenues increasing to $480.5 million from $341.5 million in the prior year period. Net income attributable to the company rose to $252.9 million, supported by substantial real estate investment activity and common stock issuances that increased total assets to $7.7 billion.

Key figure
Net income $83.7M · +11.7% YoY
4:11 PM ET 10-Q
Financial Results Doximity, Inc. DOCS

Doximity Q2 2026 Results: Net Income $34.7M, Down 44.0% YoY

Doximity reported revenue of $174.5 million for the quarter ended September 30, 2026, a slight increase from $168.5 million in the prior year. However, net income decreased significantly to $34.7 million compared to $62.1 million in the same period last year, driven by higher cost of revenue and increased research and development expenses.

Key figure
Net income $34.7M · -44.0% YoY
4:10 PM ET 10-Q
Financial Results Xeris Biopharma Holdings, Inc. XERS ▶ Call

Xeris Biopharma Holdings Q3 2026 Results: Net Income $11.3M, Up 1718.0% YoY

Xeris Biopharma reported a significant increase in total revenue to $107.2 million for the third quarter of 2026, up from $74.4 million in the prior year. While the company achieved a net income of $11.3 million for the quarter, it recorded a net loss of $17.6 million for the nine-month period, largely driven by a $30.8 million loss on debt extinguishment.

Key figure
Net income $11.3M · +1718.0% YoY
4:10 PM ET 10-Q
Financial Results Braemar Hotels & Resorts Inc. BHR

Braemar Hotels & Resorts Q3 2026 Results: Net Loss of $233M

Braemar Hotels & Resorts Inc. reported a significant net loss of $249.4 million for the quarter ended September 30, 2026, primarily driven by a $480 million termination fee. Total hotel revenue decreased to $101.6 million from $143.6 million in the prior year period, while the company recorded a $259.9 million gain on the disposition of assets and hotel properties.

Key figure
Net loss $233M
4:10 PM ET 10-Q
Financial Results Columbia Sportswear Co COLM

Columbia Sportswear Q3 2026 Results: Net Income $84.7M, Up 62.9% YoY

Columbia Sportswear reported a significant increase in net income for the third quarter of 2026, reaching $84.7 million compared to $52.0 million in the prior year, driven by higher net sales and improved operating margins. The company also saw a substantial reduction in cash and short-term investments as it executed $200 million in share repurchases during the first nine months of the year.

Key figure
Net income $84.7M · +62.9% YoY
4:10 PM ET 8-K
Financial Results Innodata Inc INOD

Innodata Financial Results

Innodata reported record Q3 2026 revenue of $95.6 million, a 53% year-over-year increase, driven by significant expansion with hyperscale customers and new program wins. The company raised its full-year 2026 revenue growth guidance to 42% or more and highlighted new initiatives in physical AI and robotics data training.

Term
Q3 2026

“Q3 was another record revenue quarter for Innodata. Revenue of $95.6 million grew 53% year-over-year and exceeded analyst consensus by approximately $12.3 million, or 15%, marking our 13th consecutive quarter of year-over-year growth.”

Rahul Singhal, CEO

“The story of the quarter is the breadth of what we are winning. A customer that represented less than 5% of our revenue a year ago became our largest customer in Q3, giving us two customers of comparable scale and meaningfully advancing our diversification.”

Rahul Singhal, CEO
4:10 PM ET 8-K
Financial Results Artivion, Inc. AORT

Artivion Financial Results

Artivion reported Q3 2026 revenue of $123.8 million, a 9% increase year-over-year, driven by strong performance in On-X and stent grafts. The company narrowed its full-year 2026 revenue guidance to $484-$492 million and is preparing for the U.S. commercial launch of NEXUS in January 2027.

Term
Q3 2026

“In the third quarter of 2026, we delivered 9% constant currency revenue growth, reflecting continued execution of our strategy to drive long-term, profitable growth through an expanding and clinically differentiated product portfolio.”

Pat Mackin, Chairman, President, and Chief Executive Officer

“Overall, we are encouraged by our third quarter performance and the progress we have made so far in 2026. With the recent PMAs of AMDS and NEXUS in the U.S., and ARCEVO LSA on track with enrollment in the ARTIZEN IDE trial, we believe we are on track to being the only company with a comprehensive aortic arch portfolio, which represents an approximately $330 million annual U.S. market opportunity.”

Pat Mackin, Chairman, President, and Chief Executive Officer
4:10 PM ET 8-K
Business Update StepStone Group Inc. STEP

StepStone Group Business Update

StepStone Group reported its second quarter fiscal year 2027 results for the period ended September 30, 2026, and declared a quarterly cash dividend of $0.33 per share. As of the quarter-end, the firm was responsible for approximately $958 billion of total capital, including $261 billion in assets under management. Although filed under Item 2.02, the press release contains only selective operational metrics and lacks a formal GAAP income statement.

4:10 PM ET 10-Q
Financial Results OppFi Inc. OPFI

OppFi Q3 2026 Results: Net Income $34.5M, Down 17.2% YoY

OppFi Inc. reported net revenue of $92.8 million for the three months ended September 30, 2026, a decrease from $104.6 million in the prior year period, primarily driven by a larger negative change in the fair value of finance receivables. The company maintained a strong liquidity position with $140.7 million in total cash and restricted cash, while total assets grew to $842.4 million following significant changes in its capital structure and the elimination of noncontrolling interests.

Key figure
Net income $34.5M · -17.2% YoY
4:10 PM ET 10-K
Financial Results Visa Inc. V

Visa FY 2026 Results: Net Income $23.5B, Up 17.2% YoY

Visa Inc. identifies structural and organizational risks including the integration of acquisitions, the competitive market for AI and cybersecurity talent, and potential voting dilution from the conversion of class B and C common stock. The company also outlines its cybersecurity program, which is integrated into its enterprise risk management framework and aligned with ISO 27002 and PCI DSS standards.

Key figure
Net income $23.5B · +17.2% YoY
4:10 PM ET 10-Q
Financial Results BlackSky Technology Inc. BKSY ▶ Call

BlackSky Technology Q3 2026 Results: Turns Profitable, Net Income $18.5M

BlackSky Technology Inc. reported a significant revenue increase to $42.8 million for the third quarter of 2026, driven by growth in space-based intelligence and AI services. The company achieved a quarterly net income of $18.5 million, a substantial improvement from the $15.3 million loss in the prior year, largely aided by a $19.7 million gain on derivatives.

Key figure
Net income $18.5M
4:10 PM ET Form 4
Insider Selling Miami International Holdings, Inc. MIAX

Miami International Holdings EVP and CIO Douglas M. Schafer Jr. Sells $1.64M of Stock

Douglas M. Schafer Jr., EVP and CIO, sold 48,000 shares of Miami International Holdings, Inc. at $34.07 to $35.00 a share (average $34.23) in 2 transactions, worth $1.64M in total between Nov 3, 2026 and Nov 4, 2026. Shares held after the trade: 387,414 (-2.0%).

Value
$1.64M
Shares
48,000
Average price
$34.23
Role
EVP and CIO
Holding change
-2.0%
Trade date
Nov 3, 2026 to Nov 4, 2026
4:10 PM ET Form 4
Insider Selling Hanover Insurance Group, Inc. THG

Hanover Insurance Group EVP Willard T. Lee Sells $2.48M of Stock

Willard T. Lee, EVP, sold 9,946 shares of Hanover Insurance Group, Inc. at $248.98 to $249.69 a share (average $249.14) in 2 transactions, worth $2.48M in total on Nov 4, 2026. Shares held after the trade: 6,004 (-27.8%).

Value
$2.48M
Shares
9,946
Average price
$249.14
Role
EVP
Holding change
-27.8%
Trade date
Nov 4, 2026
4:10 PM ET Form 4
Insider Selling Viasat Inc VSAT

Viasat SVP, Pres Viasat Government Craig Andrew Miller Sells $1.58M of Stock

Craig Andrew Miller, SVP, Pres Viasat Government, sold 22,500 shares of Viasat Inc at $70.01 to $70.38 a share (average $70.19) in 2 transactions, worth $1.58M in total on Nov 4, 2026. Shares held after the trade: 41,570 (-20.4%).

Value
$1.58M
Shares
22,500
Average price
$70.19
Role
SVP, Pres Viasat Government
Holding change
-20.4%
Trade date
Nov 4, 2026
4:10 PM ET 10-Q
Financial Results Wheeler Real Estate Investment Trust, Inc. WHLR

Wheeler Real Estate Investment Trust Q3 2026 Results: Net Loss of $6.97M

Wheeler Real Estate Investment Trust, Inc. reported 1,788,532 common shares outstanding as of November 3, 2026. The company has undergone numerous reverse stock splits in 2025 and 2026 to maintain Nasdaq compliance and manage the dilutive effects of Series D Preferred Stock redemptions and convertible note adjustments.

Key figure
Net loss $6.97M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.